These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 18497254)
1. [Unwanted drug interactions. Keeping up pharmacovigilance using databases]. Schindler B Med Monatsschr Pharm; 2008 Apr; 31(4):155-6. PubMed ID: 18497254 [No Abstract] [Full Text] [Related]
3. Collection and analysis of drug safety data in pregnancy. Moretti M Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508 [No Abstract] [Full Text] [Related]
4. [Misuse of drugs: conclusions of the pharmacovigilance workshops at La Baule, France]. Fermont I; Therapie; 2002; 57(3):283-8. PubMed ID: 12422543 [TBL] [Abstract][Full Text] [Related]
5. [Drug surveillance: the concept, the need and methods]. Moreno González A An R Acad Nac Med (Madr); 1992; 109(1):197-218; discussion 218-20. PubMed ID: 1463138 [No Abstract] [Full Text] [Related]
6. [4-year experience in drug surveillance]. Capellà D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912 [No Abstract] [Full Text] [Related]
7. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions. Fraunfelder FW; Fraunfelder FT Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050 [TBL] [Abstract][Full Text] [Related]
8. Current status of the drug safety monitoring system in Korea. Park BJ Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840 [No Abstract] [Full Text] [Related]
9. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Coloma PM; Schuemie MJ; Trifirò G; Gini R; Herings R; Hippisley-Cox J; Mazzaglia G; Giaquinto C; Corrao G; Pedersen L; van der Lei J; Sturkenboom M; Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):1-11. PubMed ID: 21182150 [TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance in India: how safe are the new drugs? How sure are we? Joshi SR; Sapatnekar SM J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970 [No Abstract] [Full Text] [Related]
12. [Direct reporting of side effects by the patient: favourable experience in the first year]. van Grootheest AC; Passier JL; van Puijenbroek EP Ned Tijdschr Geneeskd; 2005 Mar; 149(10):529-33. PubMed ID: 15782689 [TBL] [Abstract][Full Text] [Related]
13. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods]. Lagier G; Vincens M; Lefebure B; Frelon JH Therapie; 1983; 38(3):295-302. PubMed ID: 6612666 [No Abstract] [Full Text] [Related]
14. [The Spanish drug surveillance system]. Laporte JR; Capellà D Med Clin (Barc); 1994 Sep; 103(9):335-6. PubMed ID: 7967892 [No Abstract] [Full Text] [Related]
15. A model for the future conduct of pharmacovigilance. Waller PC; Evans SJ Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844 [TBL] [Abstract][Full Text] [Related]
17. European commission consultation on pharmacovigilance. Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839 [No Abstract] [Full Text] [Related]
18. [Importance of knowledge of information on adverse effects and interactions of drugs]. Stanimirović V; Babić M; Cucak S; Nikolić D; Nikolić A Srp Arh Celok Lek; 2000; 128(3-4):135-9. PubMed ID: 10932625 [No Abstract] [Full Text] [Related]